RGD Reference Report - Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.

Authors: Giaginis, C  Katsamangou, E  Tsourouflis, G  Zizi-Serbetzoglou, D  Kouraklis, G  Theocharis, S 
Citation: Giaginis C, etal., Med Sci Monit. 2009 May;15(5):BR148-56.
RGD ID: 2317461
Pubmed: PMID:19396032   (View Abstract at PubMed)

BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a ligand-activated transcription factor that forms heterodimers with the retinoid X receptors (RXRs), is overexpressed in various tumors, regulating many aspects of cancer biology. The aim of the present study was to evaluate the clinical significance of PPAR-gamma and RXR-alpha expression in pancreatic adenocarcinoma. MATERIAL/METHODS: PPAR-gamma and RXR-alpha protein expression was assessed immunohistochemically in tumoral samples of 65 pancreatic adenocarcinoma patients and statistically analyzed in relation to clinicopathological characteristics, tumor proliferative capacity, and patients' survival. RESULTS: Of the 65 adenocarcinoma patients, 49 (75%) tested positive for PPAR-gamma and 55 (85%) stained positive for RXR-alpha. RXR-alpha positivity was significantly associated with tumor proliferative capacity and PPAR-gamma positivity (p=0.022 and p=0.043, respectively). PPAR-gamma and RXR-alpha staining intensity were associated with the histopathological tumor grade (p=0.003 and p=0.038, respectively). Significant associations of PPAR-gamma staining intensity and RXR-alpha expression with tumor size were also noted (p=0.041 and p=0.038, respectively). Moderate and intense PPAR-gamma staining intensity was associated with shorter overall survival in univariate analysis (log-rank test, p=0.023) and proved to be an independent prognostic factor in multivariate analysis (p=0.045), whereas RXR-alpha failed to predict patients' survival. CONCLUSIONS: These data revealed that both PPAR-gamma and RXR-alpha were associated with pancreatic cancer characteristics. PPAR-gamma, but not RXR-alpha, was found to be an independent prognostic indicator. However, further molecular and clinical studies are required to delineate the potential clinical application of PPAR-gamma and RXR-alpha in the prognosis and management of pancreatic adenocarcinoma patients.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
pancreatic ductal carcinoma disease_progressionIEP 2317461 RGD 
pancreatic ductal carcinoma disease_progressionISOPPARG (Homo sapiens)2317461; 2317461 RGD 
pancreatic ductal carcinoma severityIEP 2317461 RGD 
pancreatic ductal carcinoma severityISORXRA (Homo sapiens)2317461; 2317461 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Pparg  (peroxisome proliferator-activated receptor gamma)
Rxra  (retinoid X receptor alpha)

Genes (Mus musculus)
Pparg  (peroxisome proliferator activated receptor gamma)
Rxra  (retinoid X receptor alpha)

Genes (Homo sapiens)
PPARG  (peroxisome proliferator activated receptor gamma)
RXRA  (retinoid X receptor alpha)


Additional Information